Amgen (AMGN) Posts Solid Q1, All Eyes Now on Repatha CV Outcomes Trial - BMO Capital

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/21/2026

1. SPY
2. WBD
3. NVDA
4. PSKY
5. TSLA
6. AMD
7. USO
8. AMC
9. META
10. NUAI

Go back to Amgen (AMGN) Posts Solid Q1, All Eyes Now on Repatha CV Outcomes Trial - BMO Capital
Amgen Inc (NASDAQ: AMGN) Delayed: 393.45 +7.80 (2.02%)
Previous Close $385.65    52 Week High $176.85 
Open $385.71    52 Week Low $133.64 
Day High $394.50    P/E 59.25 
Day Low $381.90    EPS $6.64 
Volume 1,096,647